Cantab Biopharmaceuticals Ltd is a biopharmaceutical company committed to the discovery and development of innovative drugs and drug formulations. While the Biopharmaceuticals business, based on the Cambridge Science Park, is focused on the development of "biosuperior" products, the Anti-Infectives group, based in Welwyn Garden City, has a strong portfolio of development programmes addressing the key life-threatening pathogens that are responsible for difficult to treat infections especially in the hospital setting.
Cantab Biopharmaceuticals Anti-Infectives group is committed to bringing a new generation of anti-infective agents with improved resistance profiles into development to combat the growing issue of hospital based infection. The current product pipeline has been derived by optimising the therapeutic properties of peptide-derived antibiotics against Gram-positive and Gram-negative pathogens.
Cantab BioPharmaceuticals, Cambridge, is using its extensive experience in biopharmaceutical discovery, process development and GMP manufacturing to expedite the development of biosuperiors from inception through clinical development.
Previously marketed, off-patent, biologics will be enhanced by the application of appropriate cutting-edge technologies in protein expression/engineering, process/manufacturing technology, protein conjugation, formulation and drug delivery.
Particular areas of drug characteristics that Cantab seek to improve upon are product presentation and stability, pharmacokinetics, pharmacodynamics, immunogenicity and drug delivery.